Swiss pharmaceutical manufacturer Roche has appointed commercial real estate agents Cushman & Wakefield to bring its former 88-acre manufacturing site in Clarecastle, Co. Clare to market, following the completion of what the company describes as one of the largest remediation projects of its type in Europe. The development marks a significant milestone for industrial land reuse in Ireland and carries implications for inward investment into the Midwest region.

As reported by RTÉ News, the total clean-up bill for the site now stands at €207.56m, with Roche Ireland recording pre-tax losses of €59.07m in 2025, the highest annual spend on environmental costs since the decommissioning project commenced in 2020. Over one million hours have been worked on the project to date.

The Clarecastle facility was established in 1974 as Syntex Ireland and became Roche's Irish pharmaceutical manufacturing base following the Roche Group's acquisition of the site in 1994. Roche announced its decision to exit the facility in 2015, with final production undertaken in November 2019 and pharmaceutical operations ceasing in March 2020. A buyer could not be secured at that time, and the company proceeded with full decommissioning.

The site is now being marketed with the objective of identifying an investor capable of delivering sustainable employment and long-term economic benefit to the region. Roche has framed the marketing strategy around leaving a positive legacy for the local community, Co. Clare and Ireland.

A spokeswoman for Roche Ireland said the costs for 2025 relate to executing remediation of the Clarecastle site to return it to a brownfield status, capable of attracting new investment, and added: "When the site remediation is complete, the company will have met its objectives of delivering a brownfield site with the potential to deliver sustainable jobs under a new investor and leaving a positive legacy for the local community, Clare and Ireland."

Patricia Staunton of Cushman & Wakefield described the site as a unique opportunity to reposition a strategically located asset with significant scale and infrastructure, capable of accommodating high-value enterprise. She added that the firm was working closely with Roche to ensure the marketing process delivers a successful transaction as well as meaningful long-term impact in terms of employment, investment and regional development.